
	Zileuton controls idiopathic angioedema in many patients. (Antiasthmatic Agent). : An article from: Skin & Allergy News $5.95	Business Wire : Rhodia Pharma Solutions and Critical Therapeutics Sign Long-Term Supply Agreement for Zileuton. $5.95

	Investigations towards understanding the idiosyncratic nature of zileuton toxicity : (Dissertation) $55.00


Zileuton provided clinically relevant reductions in the need for rescue medication and oral corticosteroids compared to placebo in moderate and severe PURPOSE: Zileuton Provided Clinically Relevant Reductions in the Need for Rescue Medication and Oral Corticosteroids Compared to Placebo in Moderate ... From CHEST, 10/1/05 by Mark C. Liu

Zileuton provided significant improvement in pulmonary function compared to placebo in moderate and severe asthmatics PURPOSE: Zileuton Provided Significant Improvement in Pulmonary Function Compared to Placebo in Moderate and Severe Asthmatics. METHODS: This was a randomized, placebo-controlled, double-blind, p From CHEST, 10/1/05 by William Berger

Study of oral zileuton in the treatment of moderate to severe facial acne vulgaris This study is currently recruiting patients. Sponsored by Critical Therapeutics. Tissue inflammation is a major component of the acne disease process. From Journal of Drugs in Dermatology, 5/1/05

Zileuton for maintenance treatment of chronic asthma - Tips from Other Journals Zileuton has recently been approved by the U.S. Food and Drug Administration (FDA) for prophylaxis and maintenance treatment of chronic asthma. Zileuton ... From American Family Physician, 9/1/97 by Barbara Apgar

Critical Therapeutics Initiates Pharmacokinetic Studies of Zileuton Controlled-Release Tablets; Data to support New Drug Application for twice-a-day formulation LEXINGTON, Mass. -- Critical Therapeutics, Inc. (Nasdaq: CRTX) today announced that it has initiated two definitive pharmacokinetic studies comparing ... From Business Wire, 12/20/05

Critical Therapeutics to Initiate Clinical Study of Intravenous Formulation of Zileuton; Phase I/II Asthma Study Scheduled to Begin in the First Quarter LEXINGTON, Mass. -- Critical Therapeutics, Inc. (Nasdaq: CRTX) today announced that the 30-day waiting period relating to the Company's Investigational ... From Business Wire, 12/19/05

Treating allergies & asthma There are nearly as many medications out there to treat allergies and asthma as there are allergens. The chart below provides information on some of ... From National Women's Health Report, 8/1/05

Analgesic activity of acetyl-11-keto-beta-boswellic acid, a 5-lipoxygenase-enzyme inhibitor Byline: M. Bishnoi, C. Patil, A. Kumar, S. Kulkarni Acetyl-11-keto-beta-boswellic acid (AKBA) is one of the four major pentacyclic triterpenic acids ... From Indian Journal of Pharmacology, 7/1/05 by M. Bishnoi

Home

Contact

Resources

Exchange Links

ebay